Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
The British Journal of Diabetes & Vascular Disease
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Holt, R. I.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Reviews

Review: Severe mental illness, antipsychotic drugs and the metabolic syndrome

Richard Ig Holt

Level F (MP113), Centre Block, Southampton General Hospital, Tremona Road, Southampton, SO16 6YD, UK, R.I.G.Holt{at}soton.ac.uk

The prevalence of the metabolic syndrome is increased 2—3-fold among people with severe mental illness (SMI) and may explain the high risk of cardiovascular disease in this patient group. The reason for the increase in the metabolic syndrome in people with SMI is unclear but is likely to be multifactorial, including both hereditary and environmental factors. There are concerns that antipsychotic medication may be responsible for the increased prevalence of diabetes, the metabolic syndrome and cardiovascular disease in people with SMI. While the evidence linking the antipsychotics with diabetes remains inconclusive, certain antipsychotics, notably olanzapine and clozapine are associated with weight gain and hypertriglyceridaemia. At present there is little systematic monitoring of cardiovascular risk factors in people with SMI and consequently there is a high prevalence of undiagnosed metabolic problems. The burden of cardiovascular disease and diabetes could be reduced in people with SMI if lifestyle intervention was instituted and pharmacotherapy used when indicated. The adverse effects of antipsychotic medication should be balanced with the therapeutic benefits which may be important in ensuring that patients are able to make the necessary changes to reduce the burden of diabetes and cardiovascular disease.

Key Words: severe mental illness • antipsychotics • diabetes • metabolic syndrome • cardiovascular disease.

References

  • National Institute for Clinical Excellence (NICE). Schizophrenia: core interventions in the treatment and management of schizophrenia in primary and secondary care. Clinical guidelines 1. London 2002; Available at http://www.nice.org.uk
  • Reaven GM Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37:1595-607.[Abstract]
  • Alberti KG, Zimmet P., Shaw J., IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005;366:1059-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Kahn R., Buse J., Ferrannini E., Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005;28:2289-304.[Abstract/Free Full Text]
  • Heiskanen T., Niskanen L., Lyytikainen R. et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-9.[Web of Science][Medline] [Order article via Infotrieve]
  • Straker D., Correll CU, Kramer-Ginsberg E. et al. Cost-effective screening for the metabolic syndrome in patients treated with second-generation antipsychotic medications. Am J Psychiatry 2005;162:1217-21.[Abstract/Free Full Text]
  • Kato MM, Currier MB, Gomez CM, Hall L., Gonzalez-Blanco M. Prevalence of Metabolic Syndrome in Hispanic and Non-Hispanic Patients With Schizophrenia. Prim Care Companion J Clin Psychiatry 2004;6:74-7.[Medline] [Order article via Infotrieve]
  • Littrell K., Petty R., Hilligoss N. et al. Insulin Resistance and Syndrome X Among Schizophrenia Patients. American Psychiatry Association meeting 2003.
  • Basu R., Brar JS, Chengappa KN et al. The prevalence of the metabolic syndrome in patients with schizoaffective disorder - bipolar subtype. Bipolar Disord 2004;6:314-18.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Meyer J., Loh C., Leckband SG et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract 2006;12:5-10.[CrossRef][Medline] [Order article via Infotrieve]
  • Cohn T., Prud'homme D., Streiner D., Kameh H., Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry 2004;49:753-60.[Medline] [Order article via Infotrieve]
  • McEvoy JP, Meyer JM, Goff DC et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res 2005;80:19-32.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • De Hert MA, van WR, Van ED et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res 2006;83:87-93.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Hagg S., Lindblom Y., Mjorndal T., Adolfsson R. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol 2006;21:93-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Saari KM, P Lindeman SM, Viilo KM et al. A 4-fold risk of metabolic syndrome in patients with schizophrenia: the Northern Finland 1966 Birth Cohort study. J Clin Psychiatry 2005;66:559-63.[Web of Science][Medline] [Order article via Infotrieve]
  • Lamberti JS, Olson D., Crilly JF et al. Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry 2006;163: 1273-6.[Abstract/Free Full Text]
  • Mukherjee S., Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet 1989;1:495.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Cheta D., Dumitrescu C., Georgescu M. et al. A study on the types of diabetes mellitus in first degree relatives of diabetic patients. Diabetes Metab 1990;16:11-15.[Web of Science]
  • Susser ES, Lin SP Schizophrenia after prenatal exposure to the Dutch Hunger Winter of 1944-1945. Arch Gen Psychiatry 1992;49:983-8.[Abstract/Free Full Text]
  • Brown S., Birtwistle J., Roe L., Thompson C. The unhealthy lifestyle of people with schizophrenia. Psychol Med 1999;29:697-701.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • McCreadie R., Macdonald E., Blacklock C. et al. Dietary intake of schizophrenic patients in Nithsdale, Scotland: case-control study. BMJ 1998;317:784-5.[Free Full Text]
  • Ryan MC, Thakore JH Physical consequences of schizophrenia and its treatment. The metabolic syndrome. Life Sciences 2002;71:239-57.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Appel KE, Farr CB Blood sugar reaction to insulin in psychoses. Arch Neurol Psychiatry 1929;21:145-8.[Abstract/Free Full Text]
  • Holt RIG, Peveler RC Anti-psychotic drugs and diabetes. Diabetes Obes Metab 2006;8:125-35.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Holt RI, Peveler RC Antipsychotic drugs and diabetes - an application of the Austin Bradford Hill criteria. Diabetologia 2006;49:1467-76.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Citrome L. Metabolic syndrome and cardiovascular disease. J Psychopharmacol 2005;19(suppl 6):84-93.[Abstract/Free Full Text]
  • Ascher-Svanum H., Stensland MD, Kinon BJ, Tollefson GD Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol 2005;19(suppl 6):110-17.[Abstract/Free Full Text]
  • Allison DB, Casey DE Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(suppl 7):22-31.
  • Haddad P. Weight change with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 2005;19(suppl 6):16-27.[Abstract/Free Full Text]
  • Basson BR, Kinon BJ, Taylor CC, Szymanski KA, Gilmore JA, Tollefson GD Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001;62:231-8.[Web of Science][Medline] [Order article via Infotrieve]
  • Kinon BJ, Kaiser CJ, Ahmed S., Rotelli MD, Kollack-Walker S. Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders. J Clin Psychopharmacol 2005;25:255-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353: 1209-23.[Abstract/Free Full Text]
  • Menza M., Vreeland B., Minsky S., Gara M., Radler DR, Sakowitz M. Managing atypical antipsychotic-associated weight gain: 12-month data on a multimodal weight control program. J Clin Psychiatry 2004;65:471-7.[Web of Science][Medline] [Order article via Infotrieve]
  • Pendlebury J., Haddad P., Dursun S. Evaluation of a behavioural weight management programme for patients with severe mental illness: 3 year results. Hum Psychopharmacol 2005;20:447-8.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Feeney L., Dempsey J., Moynihan F., Barry S. Changes in body mass indices of patients with schizophrenia 3 years following the introduction of a weight management programme. Ir Med J 2003;96:276-7.[Medline] [Order article via Infotrieve]
  • Jin H., Meyer JM, Jeste DV Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64.[CrossRef][Medline] [Order article via Infotrieve]
  • Hedenmalm K., Hagg S., Stahl M., Mortimer O., Spigset O. Glucose intolerance with atypical antipsychotics. Drug Saf 2002;25:1107-16.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Citrome LL Focus on the clinical ramifications of antipsychotic choice for the risk for developing type 2 diabetes mellitus. Int J Neuropsychopharmacol 2005;8(2):1-5.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Leslie DL, Rosenheck RA Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications. Am J Psychiatry 2004;161: 1709-11.[Abstract/Free Full Text]
  • Bushe C., Paton C. The potential impact of antipsychotics on lipids in schizophrenia: is there enough evidence to confirm a link? J Psychopharmacol2005; 19(suppl6):76-83.
  • Paton C., Esop R., Young C., Taylor D. Obesity, dyslipidaemias and smoking in an inpatient population treated with antipsychotic drugs. Acta Psychiatr Scand 2004;110:299-305.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Gupta S., Masand PS, Virk S. et al. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 2004;70:57-62.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Sramek JJ, Cutler NR, Shiovitz T. The effect of antipsychotics on plasma lipids. J Clin Psychopharmacol 2003;23:679-80.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Lindenmayer JP, Czobor P., Volavka J. et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6.[Abstract/Free Full Text]
  • McQuade RD, Stock E., Marcus R. et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(suppl 18):47-56.[Web of Science][Medline] [Order article via Infotrieve]
  • Kendrick T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br J Psychiatry 1996;169:733-9.[Abstract/Free Full Text]
  • Markowitz JS, Wells BG, Carson WH Interactions between antipsychotic and antihypertensive drugs. Ann Pharmacother 1995;29:603-09.[Abstract]
  • Engl J., Laimer M., Niederwanger A. et al. Olanzapine impairs glycogen synthesis and insulin signaling in L6 skeletal muscle cells. Mol Psychiatry 2005;10:1089-96.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • Ader M., Kim SP, Catalano KJ et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease: a placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005;54:862-71.[Abstract/Free Full Text]
  • Baptista T., Alvarez L., Lacruz A., de Mendoza S., Hernandez L. Glucose tolerance and serum insulin levels in an animal model of obesity induced by sub-acute or chronic administration of antipsychotic drugs. Prog Neuropsychopharmacol Biol Psychiatry 1999;23:277-87.[CrossRef][Medline] [Order article via Infotrieve]
  • Sowell MO, Mukhopadhyay N., Cavazzoni P. et al. Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo. J Clin Endocrinol Metab 2002;87: 2918-23.[Abstract/Free Full Text]
  • Sowell M., Mukhopadhyay N., Cavazzoni P. et al. Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp. J Clin Endocrinol Metab 2003;88:5875-80.[Abstract/Free Full Text]
  • Metabolic and lifestyle issues and severe mental illness - new connections to well-being. J Psychopharmacol 2005;19(suppl 6):118-22.[Free Full Text]
  • 'Schizophrenia and Diabetes 2003' Expert Consensus Meeting, Dublin, 3-4 October 2003: consensus summary. Br J Psychiatry Suppl 2004; 47:112-14.
  • Taylor D., Young C., Esop R., Paton C., Walwyn R. Testing for diabetes in hospitalised patients prescribed antipsychotic drugs. Br J Psychiatry 2004; 185:152-6.[Abstract/Free Full Text]
  • Taylor D., Young C., Mohamed R., Paton C., Walwyn R. Undiagnosed impaired fasting glucose and diabetes mellitus amongst inpatients receivIng antipsychotic drugs. J Psychopharmacol 2005;19:182-6.[Abstract/Free Full Text]
  • Subramaniam M., Chong SA, Pek E. Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia. Can J Psychiatry 2003;48: 345-7.[Medline] [Order article via Infotrieve]
  • Sernyak MJ, Gulanski B., Rosenheck R. Undiagnosed hyperglycemia in patients treated with atypical antipsychotics. J Clin Psychiatry 2005;66: 1463-7.[Web of Science][Medline] [Order article via Infotrieve]

The British Journal of Diabetes & Vascular Disease, Vol. 6, No. 5, 199-204 (2006)
DOI: 10.1177/14746514060060050301
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Holt, R. I.
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?